ACAD vs BDX
ACADIA Pharmaceuticals Inc. vs Becton Dickinson — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
67
Buy
VS
BDX
Becton Dickinson
50
Watch
| Metric | ACAD | BDX |
|---|
| AI Score |
67
|
50
|
| Price |
$29.66
|
$190.62
|
| P/E Ratio |
13.18×
|
57.45×
|
| ROE |
31.9%
|
6.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
46.1%
|
| Debt / Equity |
0.06×
|
0.69×
|
| Dividend Yield |
0.0%
|
2.0%
|
| RSI (14) |
61.2
|
77.5
|
| Beta |
0.845
|
0.258
|
| Expected Upside |
—
|
+2.4%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus BDX.
ACAD leads by 17 points.
ACAD scores 67/100 (Buy) versus BDX at 50/100 (Watch).
ACAD Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- P/E of 12.9 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- Bollinger bandwidth of 22.8% signals elevated volatility — Risk
BDX Committee View
33% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — p/e of 53.2 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 53.2 is expensive by classic value standards — Value
- ROE of only 3.8% -- cheap may mean cheap for a reason — Value
- Revenue declining -2.6% YoY -- this is not a growth story right now — Growth